# Juvenile Idiopathic Arthritis FDA approvals and PDUFA dates

Canonical: https://sec-api.dev/indications/juvenile-idiopathic-arthritis

> 4 upcoming FDA catalysts in juvenile Idiopathic Arthritis: sarilumab sar153191 (regn88, SNY) on March 2028 (primary completion); sarilumab sar153191 (regn88, SNY) on Mar to Jun 2028 (topline data readout); RINVOQ® (upadacitinib, ABBV) on June 2029 (primary completion); RINVOQ® (upadacitinib, ABBV) on Jun to Sep 2029 (topline data readout).

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, quarter only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| March 2028 | [Sarilumab sar153191 (regn88) primary completion](https://sec-api.dev/pdufa/sarilumab-sar153191-regn88) | SNY | Juvenile Idiopathic Arthritis | scheduled | "NCT02991469 (A Repeated Dose-finding Study of Sarilumab in Children and Adolescents With Systemic Juvenile Idiopathic Arthritis (SKYPS)): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2028-03-01 (ESTIMATED); Lead Sponsor Sanofi." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT02991469)) |
| Mar to Jun 2028 | [Sarilumab sar153191 (regn88) topline data readout](https://sec-api.dev/pdufa/sarilumab-sar153191-regn88) | SNY | Juvenile Idiopathic Arthritis | scheduled | "NCT02991469 (A Repeated Dose-finding Study of Sarilumab in Children and Adolescents With Systemic Juvenile Idiopathic Arthritis (SKYPS)): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2028-03-01 (ESTIMATED); Lead Sponsor Sanofi." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT02991469)) |
| June 2029 | [RINVOQ® (upadacitinib) primary completion](https://sec-api.dev/pdufa/upadacitinib) | ABBV | Juvenile Idiopathic Arthritis | scheduled | "NCT05609630 (Study of Oral Upadacitinib and Subcutaneous/Intravenous Tocilizumab to Evaluate Change in Disease Activity, Adverse Events and How Drug Moves Through the Body of Pediatric and Adolescent Participants With Active Systemic Juvenile Idiopathic Arthritis.): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-06 (ESTIMATED); Lead Sponsor AbbVie." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05609630)) |
| Jun to Sep 2029 | [RINVOQ® (upadacitinib) topline data readout](https://sec-api.dev/pdufa/upadacitinib) | ABBV | Juvenile Idiopathic Arthritis | scheduled | "NCT05609630 (Study of Oral Upadacitinib and Subcutaneous/Intravenous Tocilizumab to Evaluate Change in Disease Activity, Adverse Events and How Drug Moves Through the Body of Pediatric and Adolescent Participants With Active Systemic Juvenile Idiopathic Arthritis.): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-06 (ESTIMATED); Lead Sponsor AbbVie." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05609630)) |

## Drugs

- [Sarilumab sar153191 (regn88)](https://sec-api.dev/pdufa/sarilumab-sar153191-regn88) (SNY)
- [RINVOQ® (upadacitinib)](https://sec-api.dev/pdufa/upadacitinib) (ABBV)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/indications/juvenile-idiopathic-arthritis.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Juvenile Idiopathic Arthritis FDA approvals and PDUFA dates." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/indications/juvenile-idiopathic-arthritis

```bibtex
@misc{secapidev_indications_juvenile_idiopathic_arthritis_20261116,
  title        = {Juvenile Idiopathic Arthritis FDA approvals and PDUFA dates},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/indications/juvenile-idiopathic-arthritis}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_indications_juvenile_idiopathic_arthritis_20261116","title":"Juvenile Idiopathic Arthritis FDA approvals and PDUFA dates","publisher":"sec-api.dev","URL":"https://sec-api.dev/indications/juvenile-idiopathic-arthritis","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
